Skip to main content

Drug Discovery and Development for Novel Eye Therapeutics

Objective

Age-related macular degeneration, diabetic retinopathy, and corneal inflammation are significant causes of irreversible blindness with increasing prevalence as the EU population ages and the “diabetes epidemic” expands. There is an unmet clinical need for more effective treatments to halt or reverse these diseases.
Many EU pharmaceutical and biotechnology companies, with established processes for the synthesis and physiochemical characterisation of drugs, have bespoke chemical libraries and lead drugs with potential to treat ocular disease, but lack the expertise and infrastructure to test these drugs in relevant pre-clinical models. In parallel, academic labs with excellent infrastructure to study ocular disease, lack the industry expertise to appropriately develop drugs to enter clinical trials. Thus, clinical development of ocular therapeutics is impeded in the EU due to poor collaboration among academic and industry scientists.
3D-NET establishes a network of industry (Gadea, KalVista & RenaSci) and academic partners (UCD & UVA), who exchange knowledge and people, and who’s combined S&T expertise will enhance the discovery and development of drugs that target ocular pathologies (retinal vessel permeability, unwanted blood vessel growth, inflammation and cell degeneration). Novel ophthalmic drugs will be discovered from unbiased screens of small molecules and developed from hits/leads and selected compounds (PI3K-inhs, lipoxins, Kallikrein-inhs, HDAC-inhs, serotonin agonists), on a set of in silico/in vitro/in vivo/ex vivo preclinical models.
Expected outputs are: a) enhancing intersectoral training, career development and trans-national mobility of EU researchers, b) high impact publications/priority patent applications and c) overcoming barriers that impede industry-academia partnership in the EU inhibiting the discovery/development of new-cheaper and more effective drugs for ocular disease.

Field of science

  • /medical and health sciences/basic medicine/pathology
  • /medical and health sciences/clinical medicine/ophthalmology/retinopathy
  • /medical and health sciences/clinical medicine/endocrinology/diabetes
  • /medical and health sciences/clinical medicine/ophthalmology

Call for proposal

FP7-PEOPLE-2013-IAPP
See other projects for this call

Funding Scheme

MC-IAPP - Industry-Academia Partnerships and Pathways (IAPP)

Coordinator

UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN
Address
Belfield
4 Dublin
Ireland
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 717 579,51
Administrative Contact
Donal Doolan (Mr.)

Participants (4)

UNIVERSIDAD DE VALLADOLID
Spain
EU contribution
€ 234 967,12
Address
Plaza Santa Cruz 8 Palacio De Santa Cruz
47002 Valladolid
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Yolanda Calvo Conde (Ms.)
KALVISTA PHARMACEUTICALS LIMITED
United Kingdom
EU contribution
€ 274 693,76
Address
Phi House, Enterprise Road, Southampton Science Park
SO16 7NS Southampton
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Robert Haigh (Dr.)
GADEA BIOPHARMA SL
Spain
EU contribution
€ 175 436,17
Address
Parque Tecnologico De Leon, Edificio Usos
24009 Leon
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Samuel Alonso Martinez (Mr.)
RENASCI LIMITED
United Kingdom
EU contribution
€ 260 997,44
Address
Pennyfoot Street Biocity Nottingham
NG1 1GF Nottingham
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Rob Jones (Dr.)